Ascent Group LLC Has $1.79 Million Stock Position in Cencora, Inc. $COR

Ascent Group LLC cut its position in Cencora, Inc. (NYSE:COR) by 57.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,716 shares of the company’s stock after selling 7,738 shares during the period. Ascent Group LLC’s holdings in Cencora were worth $1,787,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in Cencora in the second quarter worth approximately $695,215,000. Artisan Partners Limited Partnership acquired a new position in shares of Cencora during the second quarter worth approximately $411,888,000. Vanguard Group Inc. lifted its holdings in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares in the last quarter. Viking Global Investors LP grew its position in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Cencora by 228.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock valued at $292,207,000 after purchasing an additional 677,952 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Stock Down 0.6%

Cencora stock opened at $338.07 on Friday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The firm’s 50-day simple moving average is $349.47 and its 200 day simple moving average is $316.22. The stock has a market cap of $65.58 billion, a PE ratio of 42.52, a price-to-earnings-growth ratio of 1.61 and a beta of 0.66.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the business posted $3.34 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Insider Activity

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the sale, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,317 shares of company stock valued at $7,009,260 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

COR has been the topic of several research reports. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. TD Cowen upped their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Robert W. Baird set a $392.00 price objective on Cencora in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $373.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.